COMP <GO>
TLSA vs ANIX // EV/EBITDA & P/E VALUATION
Tiziana Life Sciences Ltd. (NASDAQ) VS. Anixa Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: TLSA 1
— ANIX 1
■ METRIC PARITY
LAST: $0.80 (-11.57%) • MKT CAP: $115.1M
valuation
—
LAST: $3.12 (-5.45%) • MKT CAP: $114.7M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TLSA VS. ANIX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TLSA | ANIX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -6.25% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 3/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 35.8 | 56.3 | -20.54 | ANIX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $115.1M | $114.7M | $410.8K | TLSA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TLSA REV | ANIX REV | TLSA GROSS % | ANIX GROSS % | TLSA FCF | ANIX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $0 | — | — | — | -$7.2M |
| FY 2024 | — | $210.0K | — | — | — | -$7.3M |
| FY 2023 | — | $210.0K | — | — | — | -$6.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TLSA // BETA —
ANIX // BETA —